Effect of MgSO4 Administration on The Incidence of Acute Kidney Injury and Renal Function in Lung Cancer Patients Receiving Cisplatin Chemotherapy
DOI:
https://doi.org/10.36497/jri.v45i4.843Keywords:
AKI, cisplatin, lung cancer, MgSO4, renal functionAbstract
Background: Platinum-based chemotherapy is the most common lung cancer therapy currently performed with satisfactory results, but the use of platinum-based chemotherapy, such as cisplatin, can cause cisplatin-induced nephrotoxicity (CIN). MgSO4 is a substance that has been studied and is known to have a protective effect on the kidneys. This study aims to determine the effect of MgSO4 administration on the incidence of CIN in lung cancer chemotherapy patients receiving cisplatin chemotherapy.
Methods: This was a quasi-experimental study with a pre-test and post-test control group design. The study group received intravenous MgSO4 20 mEq, and the control group received standard therapy without MgSO4. The incidence of CIN was assessed based on the incidence of acute kidney injury (AKI) and renal function measured by the estimated glomerulus filtration rate (eGFR).
Results: The incidence of AKI in the treatment group was 6.67%, whereas the control group had no incidence of AKI (P=0.32). Renal function (eGFR) showed no significant difference between the treatment and control groups (P=0.86), although both groups exhibited improved renal function post-chemotherapy.
Conclusion: MgSO4 administration does not affect the incidence of AKI and renal function of lung cancer patients receiving cisplatin chemotherapy.
Downloads
References
1. Pandi A, Mamo G, Getachew D, Lemessa F, Manickam V. A brief review on lung cancer. International Journal of Pharma Research and Health Science. 2016;4(1):907–14.
2. National Cancer Institute. SEER cancer statistics review (CSR) 1975-2018 [Internet]. 2021 [cited 2023 Dec 23]. Available from: https://seer.cancer.gov/archive/csr/1975_2018/index.html
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
4. Asmara OD, Tenda ED, Singh G, Pitoyo CW, Rumende CM, Rajabto W, et al. Lung cancer in Indonesia. Journal of Thoracic Oncology. 2023;18(9):1134–45.
5. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. Journal of Thoracic Oncology. 2015;10(9):1240.
6. Majem M, Hernández-Hernández J, Hernando-Trancho F, Rodríguez de Dios N, Sotoca A, Trujillo-Reyes JC, et al. Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Clinical and Translational Oncology. 2020;22(1):21–36.
7. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.
8. Zhang J, Ye Z wei, Tew KD, Townsend DM. Cisplatin chemotherapy and renal function. Adv Cancer Res. 2021;152:305–27.
9. Duan ZY, Cai GY, Li JJ, Chen XM. Cisplatin-induced renal toxicity in elderly people. Ther Adv Med Oncol. 2020;12:1758835920923430.
10. Solanki MH, Chatterjee PK, Gupta M, Xue X, Plagov A, Metz MH, et al. Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation. Am J Physiol Renal Physiol. 2014;307(4):F369-84.
11. Hadadhania MA, Ghaffari K, Absalan A, Eghbali A, Afzal RR, Ghasemi A, et al. Magnesium supplementation may not be protective against carboplatin-induced nephrotoxicity but may be beneficial for children suffering malignancies: A randomized clinical trial. Adv Biomed Res. 2023;12:11.
12. Ashrafi F, Erfani M, Mousavi S. The effect of hydration therapy with and without magnesium sulfate on prevention of cisplatin-induced nephrotoxicity. Iranian Journal of Blood and Cancer. 2019;11(1):13–7.
13. Hase T, Miyazaki M, Ichikawa K, Yogo N, Ozawa N, Hatta T, et al. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: A prospective study. Int J Clin Oncol. 2020;25(11):1928–35.
14. Manohar S, Leung N. Cisplatin nephrotoxicity: A review of the literature. J Nephrol. 2018;31(1):15–25.
15. Fang C yan, Lou D yong, Zhou L qin, Wang J cheng, Yang B, He Q jun, et al. Natural products: Potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol Sin. 2021;42(12):1951–69.
16. Oh GS, Kim HJ, Shen A, Lee S Bin, Yang SH, Shim H, et al. New therapeutic concept of NAD redox balance for cisplatin nephrotoxicity. Biomed Res Int. 2016;2016:4048390.
17. Sauzay C, White-Koning M, Hennebelle I, Deluche T, Delmas C, Imbs DC, et al. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. Pharmacol Res. 2016;110:89–95.
18. Oronsky B, Caroen S, Oronsky A, Dobalian VE, Oronsky N, Lybeck M, et al. Electrolyte disorders with platinum-based chemotherapy: Mechanisms, manifestations and management. Cancer Chemother Pharmacol. 2017;80(5):895–907.
19. Suppadungsuk S, Phitakwatchara W, Reungwetwattana T, Pathumarak A, Phakdeekitcharoen B, Kitiyakara C, et al. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: Pilot randomized controlled trial (PRAGMATIC study). ESMO Open. 2022;7(1):100351.
20. Karagöl N. Cisplatin nefrotoxicity and treatment approaches. International Journal of PharmATA. 2023;3(1):14–22.
21. Pottel H, Björk J, Courbebaisse M, Couzi L, Ebert N, Eriksen BO, et al. Development and validation of a modified full age spectrum creatinine-based equation to estimate glomerular filtration rate: A cross-sectional analysis of pooled data. Ann Intern Med. 2021 Feb;174(2):183–91.
22. van der Burgh AC, Rizopoulos D, Ikram MA, Hoorn EJ, Chaker L. Determinants of the evolution of kidney function with age. Kidney Int Rep. 2021;6(12):3054–63.
23. Shim JS, Kim KN, Lee JS, Yoon MO, Lee HS. Magnesium intake and dietary sources among Koreans: Findings from the Korea National Health and Nutrition Examination Survey 2016–2019. Nutr Res Pract. 2023;17(1):48–61.
24. Rachman A, Wafa S, Nugroho P, Koesnoe S. The effect of mannitol addition to hydration on acute kidney injury event after high dose cisplatin chemotherapy: An ambispective cohort study. BMC Cancer. 2022;22(1):395.
25. Dierckes SJ, Ragsdale ME, Macik MR, Weddle KJ. Retrospective analysis of the incidence and severity of acute kidney injury (AKI) in patients with head and neck cancer receiving weekly cisplatin with radiotherapy (RAISe-AKI). Journal of Oncology Pharmacy Practice. 2021;27(8):1923–8.
26. Vormann J. Magnesium: Nutrition and homoeostasis. AIMS Public Health. 2016;3(2):329–40.
27. Liu D, Lu M, Lakshmanan P, Hu Z, Chen X. Increased provision of bioavailable mg through vegetables could significantly reduce the growing health and economic burden caused by mg malnutrition. Foods. 2021;10(11):2513.
28. Gopalakrishnan L, Doriya K, Kumar DS. Moringa oleifera: A review on nutritive importance and its medicinal application. Food Science and Human Wellness. 2016;5(2):49–56.
29. Workeneh BT, Uppal NN, Jhaveri KD, Rondon-Berrios H. Hypomagnesemia in the cancer patient. Kidney360. 2021;2(1):154–66.
30. Kimura T, Ozawa T, Hanai N, Hirakawa H, Suzuki H, Hosoi H, et al. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer. Journal of Otolaryngology - Head and Neck Surgery. 2018;47(1):10.
31. Kumar G, Solanki MH, Xue X, Mintz R, Madankumar S, Chatterjee PK, et al. Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol. 2017;313(2):F339-50.
32. Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One. 2014;9(7):e101902.
33. Faig J, Haughton M, Taylor RC, D’Agostino RB, Whelen MJ, Porosnicu Rodriguez KA, et al. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials. 2018;41(5):432–40.
34. Sikking C, Niggebrugge-Mentink KL, van der Sman ASE, Smit RHP, Bouman-Wammes EW, Beex-Oosterhuis MM, et al. Hydration methods for cisplatin containing chemotherapy: A systematic review. Oncologist. 2024;29(2):e173-86.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Nastiti - Lestari
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
